Iovance Biotherapeutics Inc.

06/10/2025 | Press release | Distributed by Public on 06/10/2025 15:15

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

Annual Meeting of Stockholders

On June 10, 2025, Iovance Biotherapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") virtually via live webcast. At the Annual Meeting, the Company's stockholders voted on five proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 28, 2025. At the Annual Meeting, 254,281,338 shares, or approximately 76.1% of all shares of the Company's common stock outstanding as of the record date, were represented either in person or by proxy. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter:

· Proposal 1: a proposal to elect Iain Dukes, D. Phil., Athena Countouriotis, M.D., Ryan Maynard, Wayne P. Rothbaum, Frederick G. Vogt, Ph.D., J.D., Michael Weiser, M.D., Ph.D. and Wendy Yarno to the Board of Directors (the "Board") to serve as directors until the Company's 2026 Annual Meeting of Stockholders;
· Proposal 2: a proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers;
· Proposal 3: a proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025;
· Proposal 4: a proposal to approve an amendment to the 2018 Equity Incentive Plan to increase the number of shares available for grant by 12,500,000 shares; and
· Proposal 5: a proposal to approve an amendment to the 2020 Employee Stock Purchase Plan to increase the number of shares available for grant by 1,000,000 shares.

Voting Results

Proposal 1: The voting results for the election of the director nominees were as follows:

For Against Abstain Broker Non-Vote
Dr. Dukes 142,089,795 30,706,393 1,322,491 80,162,659
Dr. Countouriotis 97,767,917 75,070,020 1,280,742 80,162,659
Mr. Maynard 166,367,869 6,453,538 1,297,272 80,162,659
Mr. Rothbaum 166,890,379 6,038,284 1,190,016 80,162,659
Dr. Vogt 165,079,137 8,467,205 572,337 80,162,659
Dr. Weiser 165,295,535 7,540,940 1,282,204 80,162,659
Ms. Yarno 166,781,324 5,674,432 1,662,923 80,162,659

Each of the above nominees was elected as a director of the Company.

Proposal 2: This proposal was approved with 158,778,895 "FOR" votes, 14,490,865 "AGAINST" votes and 848,919 "ABSTAIN" votes. There were 80,162,659 broker non-votes in connection with this proposal.

Proposal 3: This proposal was approved with 248,444,246 "FOR" votes, 4,930,624 "AGAINST" votes and 906,468 "ABSTAIN" votes. There were 0 broker non-votes in connection with this proposal.

Proposal 4: This proposal was approved with 160,920,940 "FOR" votes, 12,607,644 "AGAINST" votes and 590,095 "ABSTAIN" votes. There were 80,162,659 broker non-votes in connection with this proposal.

Proposal 5: This proposal was approved with 163,851,673 "FOR" votes, 9,804,728 "AGAINST" votes and 462,278 "ABSTAIN" votes. There were 80,162,659 broker non-votes in connection with this proposal.

Iovance Biotherapeutics Inc. published this content on June 10, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 10, 2025 at 21:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io